Alphyn Biologics, LLC – Trademark Portfolio
Entity Type: 16
Alphyn Biologics, LLC holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 5 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 5 trademarks are registered and 1 is pending. Notable registered marks include MTT, ALPHYN BIOLOGICS, MULTI-TARGET THERAPEUTICS, and IMPROVING THERAPY FOR SKIN DISEASES. The owner is based in Annapolis, MD.
3724A Thomas Point Road
Annapolis, MD 21403
Showing of trademarks Trademarks
Trademark Classifications
Alphyn Biologics, LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Alphyn Biologics, LLC have?
Alphyn Biologics, LLC has 6 U.S. trademarks filed with the USPTO. Of these, 5 registered, 1 pending.
What trademark classes does Alphyn Biologics, LLC file in?
Alphyn Biologics, LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Alphyn Biologics, LLC's most well-known trademarks?
Alphyn Biologics, LLC's registered trademark portfolio includes well-known marks such as MTT, ALPHYN BIOLOGICS, MULTI-TARGET THERAPEUTICS, and IMPROVING THERAPY FOR SKIN DISEASES. These are among 5 currently registered trademarks in the portfolio.
What is Alphyn Biologics, LLC's trademark registration success rate?
Alphyn Biologics, LLC has a 100% trademark registration rate, with 5 out of 5 resolved applications resulting in successful registration. Currently, 1 application is pending review.